181 related articles for article (PubMed ID: 34451604)
1. Molecular Engineering of Curcumin, an Active Constituent of
Ali A; Ali A; Tahir A; Bakht MA; Salahuddin ; Ahsan MJ
Plants (Basel); 2021 Jul; 10(8):. PubMed ID: 34451604
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, DFT Analyses, Antiproliferative Activity, and Molecular Docking Studies of Curcumin Analogues.
Ahsan MJ; Choudhary K; Ali A; Ali A; Azam F; Almalki AH; Santali EY; Bakht MA; Tahir A; Salahuddin
Plants (Basel); 2022 Oct; 11(21):. PubMed ID: 36365289
[TBL] [Abstract][Full Text] [Related]
3. Chemical Modification of Curcumin into Its Semi-Synthetic Analogs Bearing Pyrimidinone Moiety as Anticancer Agents.
Afzal O; Yusuf M; Ahsan MJ; Altamimi ASA; Bakht MA; Ali A; Salahuddin
Plants (Basel); 2022 Oct; 11(20):. PubMed ID: 36297760
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative Activity Predictor: A New Reliable In Silico Tool for Drug Response Prediction against NCI60 Panel.
Martorana A; La Monica G; Bono A; Mannino S; Buscemi S; Palumbo Piccionello A; Gentile C; Lauria A; Peri D
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430850
[TBL] [Abstract][Full Text] [Related]
5. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.
Lawal B; Lee CY; Mokgautsi N; Sumitra MR; Khedkar H; Wu ATH; Huang HS
Front Oncol; 2021; 11():656738. PubMed ID: 33842373
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Anticancer Activity of Curcumin Analogues Bearing a Heterocyclic Nucleus.
Ahsan MJ; Ahsan MJ
Asian Pac J Cancer Prev; 2016; 17(4):1739-44. PubMed ID: 27221847
[TBL] [Abstract][Full Text] [Related]
8. In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors.
Saeed MEM; Yücer R; Dawood M; Hegazy MF; Drif A; Ooko E; Kadioglu O; Seo EJ; Kamounah FS; Titinchi SJ; Bachmeier B; Efferth T
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409325
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel compound (β-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin.
Tyagi AK; Prasad S; Yuan W; Li S; Aggarwal BB
Invest New Drugs; 2015 Dec; 33(6):1175-86. PubMed ID: 26521943
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
El-Sherief HAM; Youssif BGM; Abbas Bukhari SN; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Eur J Med Chem; 2018 Aug; 156():774-789. PubMed ID: 30055463
[TBL] [Abstract][Full Text] [Related]
11. Curcumin effects on cell proliferation, angiogenesis and metastasis in colorectal cancer.
Calibasi-Kocal G; Pakdemirli A; Bayrak S; Ozupek NM; Sever T; Basbinar Y; Ellidokuz H; Yigitbasi T
J BUON; 2019; 24(4):1482-1487. PubMed ID: 31646795
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Anticancer Effects of Brominated Plastoquinone Analogs with Promising Cytotoxic Activity in MCF-7 Breast Cancer Cells via Cell Cycle Arrest and Oxidative Stress Induction.
Jannuzzi AT; Yilmaz Goler AM; Bayrak N; Yıldız M; Yıldırım H; Karademir Yilmaz B; Shilkar D; Venkatesan RJ; Jayaprakash V; TuYuN AF
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890076
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative Effects of Curcumin Different Types of Breast Cancer.
Guneydas G; Topcul MR
Asian Pac J Cancer Prev; 2022 Mar; 23(3):911-917. PubMed ID: 35345363
[TBL] [Abstract][Full Text] [Related]
14.
Liang Y; Zhao J; Zou H; Zhang J; Zhang T
Food Funct; 2021 Nov; 12(21):10667-10675. PubMed ID: 34604873
[TBL] [Abstract][Full Text] [Related]
15. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1).
Penthala NR; Ketkar A; Sekhar KR; Freeman ML; Eoff RL; Balusu R; Crooks PA
Bioorg Med Chem; 2015 Nov; 23(22):7226-33. PubMed ID: 26602084
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
17. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
20. Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: A review.
Hosseini A; Hosseinzadeh H
Biomed Pharmacother; 2018 Mar; 99():411-421. PubMed ID: 29367110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
